<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this open-label trial, ten male patients with active <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo> were enrolled </plain></SENT>
<SENT sid="1" pm="."><plain>Initially, two infliximab infusions (5 mg/kg) were given at weeks 0 and 2 </plain></SENT>
<SENT sid="2" pm="."><plain>The patients continued to receive conventional therapy on recurrence of severe <z:hpo ids='HP_0000554'>uveitis</z:hpo> (RSU) attack </plain></SENT>
<SENT sid="3" pm="."><plain>The patients with further attack were regularly given infliximab infusions every 8 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>In cases of further RSU attacks, the infusion interval was reduced to 6 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>The total follow-up period was 3 years </plain></SENT>
<SENT sid="6" pm="."><plain>The patients were monitored for RSU, visual acuity and adverse effects </plain></SENT>
<SENT sid="7" pm="."><plain>Reduction in the doses of <z:chebi fb="2" ids="8378">prednisolone</z:chebi> was also monitored </plain></SENT>
<SENT sid="8" pm="."><plain>After receiving two infliximab infusions at weeks 0 and 2, three patients remained attack-free and seven patients had another RSU attack between 8th and 47th week </plain></SENT>
<SENT sid="9" pm="."><plain>These patients were regularly given infliximab at 8-week intervals </plain></SENT>
<SENT sid="10" pm="."><plain>Five out of seven patients remained attack-free </plain></SENT>
<SENT sid="11" pm="."><plain>In two patients who had further attack, infusion frequency was increased to 6 weeks </plain></SENT>
<SENT sid="12" pm="."><plain>There was a remarkable improvement in visual acuity with no significant adverse reaction except mild <z:hpo ids='HP_0011947'>respiratory tract infection</z:hpo> (two patients), <z:hpo ids='HP_0002315'>headache</z:hpo> (one patient) and mild infusion reaction (one patient) </plain></SENT>
<SENT sid="13" pm="."><plain>Infliximab is a safe and effective drug for the management of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet</z:e>'s <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Selection of optimal dose and frequency of infusion required standardization for individual patient </plain></SENT>
</text></document>